v3.26.1
Summary of Significant Accounting Policies (Details Narrative)
12 Months Ended
Dec. 31, 2025
USD ($)
Segment
Dec. 31, 2024
USD ($)
Cash, FDIC insured amount $ 250,000  
Revenue $ 1,123,000 $ 43,000
Number of reportable segments | Segment 1  
Research and development $ 6,269,000 6,025,000
Inventory 189,000 0
Marketing expenses 290,000 413,000
Depreciation 2,000 0
Depreciation expense $ 2,000,000 0
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Customer A [Member]    
Concentration Risk, Percentage 22.90%  
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Customer B [Member]    
Concentration Risk, Percentage 22.00%  
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Customer C [Member]    
Concentration Risk, Percentage 20.70%  
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Three Customer [Member]    
Concentration Risk, Percentage 10.00%  
Research and Development Expense [Member]    
Marketing expenses $ 73,000 0
RenovoCath [Member]    
Payments received from clinical sites $ (344,000) $ (118,000)